Last reviewed · How we verify

Ciprodex and 2% NAC

St. Paul's Hospital, Canada · FDA-approved active Small molecule Quality 3/100

Ciprodex and 2% NAC is a Small molecule drug developed by St. Paul's Hospital, Canada. It is currently FDA-approved. Also known as: Ciprodex with 2% N-Acetylcysteine.

At a glance

Generic nameCiprodex and 2% NAC
Also known asCiprodex with 2% N-Acetylcysteine
SponsorSt. Paul's Hospital, Canada
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ciprodex and 2% NAC

What is Ciprodex and 2% NAC?

Ciprodex and 2% NAC is a Small molecule drug developed by St. Paul's Hospital, Canada.

Who makes Ciprodex and 2% NAC?

Ciprodex and 2% NAC is developed and marketed by St. Paul's Hospital, Canada (see full St. Paul's Hospital, Canada pipeline at /company/st-paul-s-hospital-canada).

Is Ciprodex and 2% NAC also known as anything else?

Ciprodex and 2% NAC is also known as Ciprodex with 2% N-Acetylcysteine.

What development phase is Ciprodex and 2% NAC in?

Ciprodex and 2% NAC is FDA-approved (marketed).

Related